GlassScriptPhysician profile
Andrew Dawson
NPI 1912353533
$36,421.21
in general payments reported to CMS, 2019-2025
30 companies · $3,311 in 2025
The $3,311 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $159 · 2021: $26.61 · 2022: $538 · 2023: $18K · 2024: $13K · 2025: $3,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $4,267 · Consulting Fee: $1,750 · Travel and Lodging: $153 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,087.50 |
| Food and Beverage | $4,267.45 |
| Consulting Fee | $1,750.00 |
| Travel and Lodging | $152.83 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,361.54 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $2,209.31 | 2023-2025 | |
| Lundbeck LLC | $502.66 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $438.93 | 2019-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $409.81 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Ucb, INC. | $396.00 | 2019-2022 | |
| Mdd US Operations, LLC | $259.75 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $203.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $186.11 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $165.79 | 2019-2025 | Ingrezza, Ongentys |
| Ge Healthcare | $149.68 | 2023-2024 | |
| Amgen INC. | $134.19 | 2019-2023 | Aimovig |
| Alkermes, INC. | $125.00 | 2019 | |
| Greenwich Biosciences, INC. | $124.99 | 2019 | |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $99.28 | 2024-2025 | Zembrace Symtouch |
| Acorda Therapeutics, INC | $79.75 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $74.53 | 2023 | Trudhesa |
| Neurelis, INC. | $61.05 | 2023-2025 | Valtoco |
| Upsher-Smith Laboratories LLC | $48.10 | 2023 | |
| Eisai INC. | $41.89 | 2024 | |
| Axsome Therapeutics, INC. | $40.95 | 2025 | Symbravo |
| Genentech USA, INC. | $36.48 | 2025 | Ocrevus Zunovo |
| Vertical Pharmaceuticals, LLC | $35.39 | 2019 | |
| Sk Life Science, INC. | $34.06 | 2025 | |
| Medtronic, INC. | $21.99 | 2025 | Percept PC Brainsense |
| Avanir Pharmaceuticals, INC. | $16.71 | 2019 | |
| Tg Therapeutics, INC. | $15.94 | 2025 | |
| Exact Sciences Corporation | $14.39 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.